Short-course early outpatient remdesivir prevents severe disease due to COVID-19 in organ transplant recipients during the omicron BA.2 wave
Open Access
- 11 January 2023
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (1) , 78-83
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 InfectionAmerican Journal of Kidney Diseases, 2022
- Considerable escape of SARS-CoV-2 Omicron to antibody neutralizationNature, 2021
- Early Remdesivir to Prevent Progression to Severe Covid-19 in OutpatientsNew England Journal of Medicine, 2021
- Real-World Effectiveness of Remdesivir in Adults Hospitalized With Coronavirus Disease 2019 (COVID-19): A Retrospective, Multicenter Comparative Effectiveness StudyClinical Infectious Diseases, 2021
- Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021MMWR. Morbidity and Mortality Weekly Report, 2021
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant RecipientsNew England Journal of Medicine, 2021
- Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant RecipientsTransplantation, 2021
- COVID-19 in solid organ transplant recipients: A systematic review and meta-analysis of current literatureTransplantation Reviews, 2021
- Coronavirus Disease 2019 in Solid Organ Transplant: A Multicenter Cohort StudyClinical Infectious Diseases, 2020
- COVID-19 in solid organ transplant recipients: Initial report from the US epicenterAmerican Journal of Transplantation, 2020